Literature DB >> 31373141

High occurrence of small intestinal bacterial overgrowth in primary biliary cholangitis.

Jeremy Liu Chen Kiow1, Catherine Vincent1, Sacha Sidani1, Mickael Bouin1.   

Abstract

BACKGROUND: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease affecting mainly middle-aged women. An alteration in intestinal motility has been well documented in cirrhosis predisposing to small intestinal bacterial overgrowth (SIBO). Patients with PBC frequently complain of various gastrointestinal symptoms compatible with SIBO. No study has specifically been published to this day to determine the occurrence of SIBO in PBC. Our objective was to determine the prevalence of SIBO in patients with PBC.
METHODS: Retrospective study from 2010 to 2018. All patients diagnosed with PBC during this period had a systematic screening for SIBO in their diagnostic workup. The diagnosis of SIBO was made by a carbohydrate breath test (lactulose and/or glucose). Clinical and paraclinical factors of patients were compared with a control group of healthy subjects. KEY
RESULTS: Ninety-eight subjects were included in the study (mean age 49, range 21-88 years) including 58 patients with PBC and 40 healthy subjects. The PBC group was older than the control group (mean age 56, range 31-88 vs 39, range 21-62 years; P < .001), but identical for gender and body mass index. The prevalence of SIBO was higher in PBC versus controls (32.8% vs 2.5%; P < .001). The PBC group with SIBO had significantly more diarrhea (78.9% vs 35.9%; P < .05) than the PBC group without SIBO, but the prevalence of abdominal pain and bloating was similar. CONCLUSIONS &amp; INFERENCES: The high occurrence of SIBO in PBC may explain some of the frequently reported gastrointestinal symptoms. This study justifies the systematic screening for SIBO in PBC.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  diarrhea; primary biliary cholangitis; small intestinal bacterial overgrowth; symptoms

Year:  2019        PMID: 31373141     DOI: 10.1111/nmo.13691

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  6 in total

Review 1.  Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics.

Authors:  Ji-Won Park; Jung-Hee Kim; Sung-Eun Kim; Jang Han Jung; Myoung-Kuk Jang; Sang-Hoon Park; Myung-Seok Lee; Hyoung-Su Kim; Ki Tae Suk; Dong Joon Kim
Journal:  Biomedicines       Date:  2022-05-31

2.  Predictors of Small Intestinal Bacterial Overgrowth in Symptomatic Patients Referred for Breath Testing.

Authors:  Jeremy Liu Chen Kiow; Ratiba Bellila; Amelie Therrien; Sacha Sidani; Mickael Bouin
Journal:  J Clin Med Res       Date:  2020-09-21

3.  Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis.

Authors:  Usha Gungabissoon; Daniel C Gibbons; Gema Requena; Andrea Ribeiro de Souza; Helen Smith
Journal:  BMJ Open Gastroenterol       Date:  2022-08

Review 4.  Intestinal homeostasis in autoimmune liver diseases.

Authors:  Qiaoyan Liu; Wei He; Ruqi Tang; Xiong Ma
Journal:  Chin Med J (Engl)       Date:  2022-07-20       Impact factor: 6.133

Review 5.  Gut-Liver Axis and Inflammasome Activation in Cholangiocyte Pathophysiology.

Authors:  Luca Maroni; Elisabetta Ninfole; Claudio Pinto; Antonio Benedetti; Marco Marzioni
Journal:  Cells       Date:  2020-03-17       Impact factor: 6.600

Review 6.  The Gut-Liver Axis in Cholestatic Liver Diseases.

Authors:  Andreas Blesl; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-03-21       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.